Q2
BLSM — Q2 2026 Financial Report Analysis
BlossomHill's first quarterly report as a public company shows R&D spending up 70% year over year to $21.4 million and a $23.8 million net loss, with pre-IPO cash down to $95.4 million and an August IPO that raised $151.7 million net funding operations only into Q2 2028.